The stock of the week “Idorsia”

This week, an interesting stock to look at is Idorsia. Idorsia is a high-potential biopharmaceutical company, that specialises in the discovery, development, and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. After Actelion was bought by Johnson & Johnson in 2017, the Actelion founders Jean-Paul and Martine Clozel founded Idorsia in 2017. The company is headquartered in Allschwil, Switzerland.

• Attention buzz is currently "extreme”.

• Financial social media sentiment is highly positive both in absolute and relative terms - compared to the sentiment of the sector and the sentiment of the stock index.

• Analysts' consensus rating is "strong buy" - out of the 12 bank analysts covering the company, 7 recommend buying the stock. 4 recommend holding it and 1 analyst recommends selling it. The upside potential of the stock price expected by the analysts on average over the next 6-12 months is currently ca 127.71% (reference close of business 25/07/22)